AR014514A1 - Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance - Google Patents

Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance

Info

Publication number
AR014514A1
AR014514A1 ARP990100346A ARP990100346A AR014514A1 AR 014514 A1 AR014514 A1 AR 014514A1 AR P990100346 A ARP990100346 A AR P990100346A AR P990100346 A ARP990100346 A AR P990100346A AR 014514 A1 AR014514 A1 AR 014514A1
Authority
AR
Argentina
Prior art keywords
polinucleotide
isolated
polypeptide
expression vector
polynucleotides
Prior art date
Application number
ARP990100346A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR014514A1 publication Critical patent/AR014514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Polinucleotidos aislados que codifican polipéptidos de tumor de pulmon. Estos polinucleotidos comprenden una secuencia de nucleotidos seleccionada delgrupo consistente en: (a) secuencias provistas en SEQ. ID. NO.: 1-11, 19, 22- 25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139,143-149, 151-154, y 156-158; (b) secuencias complementarias para una secuencia provista en SEQ. ID. NO.: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79,80, 86, 89, 90, 102-107, 109, 139, 143-149, 151-154, y 156-158; y (c) variantes de las secuencias de (a) y (b). Los polipéptidos aislados comprenden al menosuna porcion inmunogénica de una proteína de tumor pulmonar, o de una variante de ella. Vectores de expresion que comprendenlos polinucleotidos; célulashuéspedes transformadas o transinfectadas con estos vectores de expresion. Las proteínas de fusion comprenden un primer y un segundo polipéptido, o bien, elpolipéptido y un antígeno de tumor de pulmon conocido. Las composiciones farmacéuticas comprenden uno o más de los polipéptidos codificados por unpolinucleotido que comprende una secuencia seleccionada del grupo que consiste de (a) secuencias provistas en SEQ. ID. NO.: 1 a 181; (b) complementos de lassecuencias provistas en SEQ. ID. NO.: 1 a 181; (c) variantes de las secuencias de (a) y (b); proteínas de fusion, o polinucleotidos, y un vehículofisiologicamente aceptable. Las vacunas comprenden uno o más de los polipéptidos, proteínas de fusion, o polinucleotidos, combinados con unmejorador de respuesta inmune. Los métodos para inhibir el desarrollo de cáncer de pulmon en un paciente consisten en administrar a un paciente una cantidadeficaz de al menos una de las composiciones farmacéuticas y/o vacunas mencionadas. Métodos para detectar cáncer de pulmon en un paciente consisten en
ARP990100346A 1998-01-28 1999-01-28 Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance AR014514A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1502298A 1998-01-28 1998-01-28
US1502998A 1998-01-28 1998-01-28
US4083198A 1998-03-18 1998-03-18
US4082898A 1998-03-18 1998-03-18
US12219198A 1998-07-23 1998-07-23
US12219298A 1998-07-23 1998-07-23
US21924598A 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
AR014514A1 true AR014514A1 (es) 2001-02-28

Family

ID=27567530

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100346A AR014514A1 (es) 1998-01-28 1999-01-28 Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance

Country Status (13)

Country Link
EP (1) EP1051489A2 (es)
JP (1) JP2002516659A (es)
KR (1) KR20010034436A (es)
CN (1) CN1292029A (es)
AR (1) AR014514A1 (es)
AU (1) AU2344399A (es)
BR (1) BR9907259A (es)
CA (1) CA2319117A1 (es)
ID (1) ID27813A (es)
IL (1) IL137417A0 (es)
NO (1) NO20003853L (es)
WO (1) WO1999038973A2 (es)
ZA (1) ZA99693B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
WO2000026241A2 (en) * 1998-10-28 2000-05-11 Rigel Pharmaceuticals, Inc. Novel compositions and methods of screening for t-cell and b-cell activation modulators
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000035473A2 (en) * 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000046370A1 (en) * 1999-02-04 2000-08-10 Board Of Trustees Of The University Of Illinois P37ing1 compositions and methods of use
WO2000048625A2 (en) 1999-02-19 2000-08-24 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
ATE399793T1 (de) * 1999-04-02 2008-07-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1187915A2 (en) * 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6914132B1 (en) 1999-06-30 2005-07-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004500029A (ja) 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US6667154B1 (en) 1999-06-30 2003-12-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
WO2001021653A2 (en) * 1999-09-23 2001-03-29 Corixa Corporation Ovarian tumor antigen and methods of use therefor
EP1661997A1 (en) * 1999-12-01 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001253388A1 (en) * 2000-04-14 2001-10-30 Incyte Genomics, Inc. Molecules associated with human reproduction
US20020099012A1 (en) * 2000-06-29 2002-07-25 Tongtong Wang Compositions and methods for the therapy and diagnosis of lung cancer
EP1343886A2 (en) * 2000-07-11 2003-09-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2001270638A1 (en) * 2000-07-19 2002-01-30 Bayer Aktiengesellschaft Regulation of human airway trypsin protease-like enzyme
TWI317380B (en) * 2000-08-28 2009-11-21 Teijin Ltd Airway-specific trypsin-like enzymes and method of using the same
US7348406B2 (en) 2001-01-16 2008-03-25 Serono Genetics Institute S.A. Metabolic gene polynucleotides and polypeptides and uses thereof
US7226994B2 (en) 2001-01-18 2007-06-05 Cambridge University Technical Services Limited Cell surface expressed marker of pluripotency
GB0101300D0 (en) * 2001-01-18 2001-02-28 Univ Cambridge Tech Primordial germ cell genes
EP1402031A2 (en) 2001-06-21 2004-03-31 Isis Innovation Limited Atopy
AU2007216892B2 (en) * 2002-08-16 2011-02-10 Agensys, Inc. Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20060094649A1 (en) * 2002-12-10 2006-05-04 Keogh Elissa A Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
MX2007006441A (es) * 2004-11-30 2007-08-14 Johnson & Johnson Prognosis de cancer de pulmon.
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
EP2423333A1 (en) * 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2010030167A2 (en) * 2008-09-12 2010-03-18 Cancer Research Initiative Foundation Method of detection and diagnosis of oral and nasopharyngeal cancers
CN101891802B (zh) * 2009-08-11 2011-11-16 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或衍生产品及其应用
CN101921313B (zh) * 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或其衍生产品及应用
GB201104286D0 (en) * 2011-03-15 2011-04-27 Randox Lab Ltd Glutathione S-transferase omega 1 wild type specific antibody
CN103958679A (zh) * 2011-09-09 2014-07-30 转基因股份有限公司 变异型α-辅肌动蛋白-4的抗体
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP3440101B1 (en) * 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
CN110669104B (zh) * 2019-10-30 2021-11-05 上海交通大学 一组来源于人外周血单核细胞的标志物及其应用
CN112500467B (zh) * 2020-12-14 2022-05-24 上海交通大学 一种生物活性肽rrecpsdecgagvf及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor

Also Published As

Publication number Publication date
CN1292029A (zh) 2001-04-18
ID27813A (id) 2001-04-26
WO1999038973A3 (en) 1999-12-09
NO20003853D0 (no) 2000-07-27
AU2344399A (en) 1999-08-16
KR20010034436A (ko) 2001-04-25
IL137417A0 (en) 2001-07-24
JP2002516659A (ja) 2002-06-11
BR9907259A (pt) 2002-01-22
NO20003853L (no) 2000-09-27
EP1051489A2 (en) 2000-11-15
ZA99693B (en) 1999-10-21
CA2319117A1 (en) 1999-08-05
WO1999038973A2 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
AR014514A1 (es) Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance
TWI285648B (en) Compositions and methods for WT1 specific immunotherapy
AR032173A1 (es) Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer
ES2332590T3 (es) Dimero peptidico.
CA2158455A1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998004702A3 (en) Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
JP2019537562A5 (es)
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
DK0464124T3 (da) Peptid, immunogen sammensætning og vaccine eller medicinsk præparat, fremgangsmåde til immunisering af et pattedyr mod LHRH og fremgangsmåde til forbedring af kødkvaliteten hos grise
US8309096B2 (en) Fusion protein
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
PE20001287A1 (es) Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral
KR102166549B1 (ko) 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
CN100393356C (zh) 用于癌症治疗的经修饰的细胞因子
CA2353802A1 (en) New protective antigen of group a streptococci
BR9908476A (pt) Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae
HRP20110729T1 (hr) PLAZMIDI KOJI KODIRAJU VARIJANTE p185neu PROTEINSKE SEKVENCIJE I NJIHOVA TERAPIJSKA UPOTREBA
CN1404527A (zh) Tlp肽以及编码它们的dna序列
WO2020072371A1 (en) Melanoma canine vaccine compositions and methods of use thereof
NO20011263D0 (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav